← Back to Search

Radiation

Interventional for Prostate Cancer

Q: Are there any available vacancies for potential participants in this research study?

<p>Indeed, as indicated on clinicaltrials.gov, this study is currently in the phase of recruiting patients. The trial was initially posted on December 11th, 2023 and last updated on January 25th, 2024. The research team aims to enroll a total of 20 participants from a single site.</p>

Q: What is the overall patient enrollment count for this particular research investigation?

<p>Indeed, as per the information available on clinicaltrials.gov, this trial is actively seeking eligible participants. The trial was initially posted on December 11th, 2023 and last updated on January 25th, 2024. The study aims to enroll a total of 20 patients at one specific location.</p>

N/A

Recruiting

Led By Danny Vesprini, M.D.

Research Sponsored by Sunnybrook Health Sciences Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Tumour nodule visible on MRI occupying <50% of prostate on any axial slice and <50% prostate volume

MRI-visible tumour(s) of PIRADS v2 grade 3 or higher on T2 and diffusion-weighted imaging and/or dynamic contrast-enhanced imaging (multiparametric MRI or mpMRI) with concordant pathology

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 years

Awards & highlights

Study Summary

This trial is looking at a new treatment for men with prostate cancer. The treatment involves giving a targeted dose of radiation to the prostate. The goal of the trial is to develop a protocol for this treatment

Who is the study for?

Men aged 18 or older with intermediate risk localized prostate cancer, Gleason score between 3+3 and 4+3, MRI stage T2 or less. They must have a visible tumor on MRI that's less than half the size of the prostate and PSA <20 ng/ml. Short-term hormone therapy is allowed.Check my eligibility

What is being tested?

The trial tests a new way to give radiotherapy for prostate cancer using an MR Linac machine. It aims to tailor the radiation dose specifically to each patient's tumor, potentially reducing side effects by either increasing or decreasing the dose as needed.See study design

What are the potential side effects?

Potential side effects include acute and late urinary (GU) and gastrointestinal (GI) toxicity which can affect bladder and bowel function respectively, as well as possible impacts on sexual quality of life.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My prostate tumor is visible on MRI and occupies less than half of my prostate.

Select...

My MRI shows a tumor with a grade 3 or higher rating.

Select...

My cancer is at an early stage, not beyond T2 according to MRI results.

Select...

I am a man aged 18 years or older.

Select...

My prostate cancer has a Gleason score of 3+3, 3+4, or 4+3.

Select...

My prostate cancer diagnosis was confirmed with a biopsy and needs intensive radiation treatment.

Select...

I can take care of myself and perform light activities.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Technical Feasibility

Secondary outcome measures

Acute and Late Toxicities

Trial Design

1Treatment groups

Experimental Treatment

Group I: InterventionalExperimental Treatment1 Intervention

All radiotherapy will be delivered on the MR-linac

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor

656 Previous Clinical Trials

1,551,288 Total Patients Enrolled

34 Trials studying Prostate Cancer

12,618 Patients Enrolled for Prostate Cancer

Danny Vesprini, M.D.Principal InvestigatorSunnybrook Health Sciences Centre

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available vacancies for potential participants in this research study?

"Indeed, as indicated on clinicaltrials.gov, this study is currently in the phase of recruiting patients. The trial was initially posted on December 11th, 2023 and last updated on January 25th, 2024. The research team aims to enroll a total of 20 participants from a single site."

Answered by AI

What is the overall patient enrollment count for this particular research investigation?

"Indeed, as per the information available on clinicaltrials.gov, this trial is actively seeking eligible participants. The trial was initially posted on December 11th, 2023 and last updated on January 25th, 2024. The study aims to enroll a total of 20 patients at one specific location."

Answered by AI

Recent research and studies

CA: A Cancer Journal for CliniciansJournal

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Sung, Hyuna, Jacques Ferlay, Rebecca L. Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, and Freddie Bray. 2021. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries”. CA: A Cancer Journal for Clinicians. Wiley. doi:10.3322/caac.21660.

clinicaltrials.govStudy

De-escalated Dose SBRT in Localized Prostate Cancer (DESTINATION-MRL)

2023. "De-escalated Dose SBRT in Localized Prostate Cancer (DESTINATION-MRL)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06177093.